{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:19:21Z","timestamp":1793848761595,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["26460194"],"award-info":[{"award-number":["26460194"]}]},{"name":"JSPS KAKENHI","award":["26927005"],"award-info":[{"award-number":["26927005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00228-016-2116-z","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T03:49:45Z","timestamp":1472183385000},"page":"1463-1470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Hikaru","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-3789","authenticated-orcid":false,"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"2116_CR1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","volume":"32","author":"B Lalovic","year":"2004","unstructured":"Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447\u2013454","journal-title":"Drug Metab Dispos"},{"key":"2116_CR2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tips.2013.02.001","volume":"34","author":"KT Olkkola","year":"2013","unstructured":"Olkkola KT, Kontinen VK, Saari TI, Kalso EA (2013) Does the pharmacology of oxycodone justify its increasing use as an analgesic? Trends Pharmacol Sci 34:206\u2013214","journal-title":"Trends Pharmacol Sci"},{"key":"2116_CR3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/clpt.1992.176","volume":"52","author":"KP Leow","year":"1992","unstructured":"Leow KP, Smith MT, Williams B, Cramond T (1992) Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52:487\u2013495","journal-title":"Clin Pharmacol Ther"},{"key":"2116_CR4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","volume":"160","author":"CF Samer","year":"2010","unstructured":"Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160:907\u2013918","journal-title":"Br J Pharmacol"},{"key":"2116_CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00228-011-1093-5","volume":"68","author":"TN Andreassen","year":"2012","unstructured":"Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstr\u00f6m S, Kaasa S, Dale O (2012) Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol 68:55\u201364","journal-title":"Eur J Clin Pharmacol"},{"key":"2116_CR6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1177\/0091270010388033","volume":"51","author":"T Naito","year":"2011","unstructured":"Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, Kagawa Y, Kawakami J (2011) CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol 51:1529\u20131538","journal-title":"J Clin Pharmacol"},{"key":"2116_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","volume":"7","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K (2015) Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 7:17\u201329","journal-title":"World J Gastrointest Oncol"},{"key":"2116_CR8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","volume":"48","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A (2013) Cancer cachexia\u2014pathophysiology and management. J Gastroenterol 48:574\u2013594","journal-title":"J Gastroenterol"},{"key":"2116_CR9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1470-2045(03)01034-9","volume":"4","author":"KA Slaviero","year":"2003","unstructured":"Slaviero KA, Clarke SJ, Rivory LP (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224\u2013232","journal-title":"Lancet Oncol"},{"key":"2116_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434\u2013438","journal-title":"Clin Pharmacol Ther"},{"key":"2116_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","volume":"36","author":"ET Morgan","year":"2008","unstructured":"Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205\u2013216","journal-title":"Drug Metab Dispos"},{"key":"2116_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dmpk.2014.09.004","volume":"30","author":"H Mimura","year":"2015","unstructured":"Mimura H, Kobayashi K, Xu L, Hashimoto M, Ejiri Y, Hosoda M, Chiba K (2015) Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4. Drug Metab Pharmacokinet 30:105\u2013110","journal-title":"Drug Metab Pharmacokinet"},{"key":"2116_CR13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687\u20131693","journal-title":"Drug Metab Dispos"},{"key":"2116_CR14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jcph.112","volume":"53","author":"T Naito","year":"2013","unstructured":"Naito T, Tashiro M, Ishida T, Ohnishi K, Kawakami J (2013) Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. J Clin Pharmacol 53:812\u2013818","journal-title":"J Clin Pharmacol"},{"key":"2116_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2010.10.261","volume":"42","author":"BJ Laird","year":"2011","unstructured":"Laird BJ, Scott AC, Colvin LA, McKeon AL, Murray GD, Fearon KC, Fallon MT (2011) Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manag 42:1\u201311","journal-title":"J Pain Symptom Manag"},{"key":"2116_CR16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1200\/JCO.2011.39.8784","volume":"30","author":"W Breitbart","year":"2012","unstructured":"Breitbart W, Alici Y (2012) Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 30:1206\u20131214","journal-title":"J Clin Oncol"},{"key":"2116_CR17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-012-1266-x","volume":"68","author":"T Naito","year":"2012","unstructured":"Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J (2012) Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol 68:1411\u20131418","journal-title":"Eur J Clin Pharmacol"},{"key":"2116_CR18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0885-3924(00)00199-8","volume":"20","author":"RJ Dunlop","year":"2000","unstructured":"Dunlop RJ, Campbell CW (2000) Cytokines and advanced cancer. J Pain Symptom Manag 20:214\u2013232","journal-title":"J Pain Symptom Manag"},{"key":"2116_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3940(98)00060-3","volume":"242","author":"G Farkas","year":"1998","unstructured":"Farkas G, M\u00e1rton J, Nagy Z, M\u00e1ndi Y, Tak\u00e1cs T, Deli MA, Abrah\u00e1m CS (1998) Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6. Neurosci Lett 242:147\u2013150","journal-title":"Neurosci Lett"},{"key":"2116_CR20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0024-3205(95)00008-T","volume":"56","author":"A Saija","year":"1995","unstructured":"Saija A, Princi P, Lanza M, Scalese M, Aramnejad E, De Sarro A (1995) Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 56:775\u2013784","journal-title":"Life Sci"},{"key":"2116_CR21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495","journal-title":"Lancet Oncol"},{"key":"2116_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0029665108007131","volume":"67","author":"DC McMillan","year":"2008","unstructured":"McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67:257\u2013262","journal-title":"Proc Nutr Soc"},{"key":"2116_CR23","volume-title":"AJCC cancer staging manual (7th edition)","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual (7th edition). Springer, New York, NY"},{"key":"2116_CR24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89:735\u2013740","journal-title":"Clin Pharmacol Ther"},{"key":"2116_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3349\/ymj.2011.52.1.113","volume":"52","author":"SJ Chung","year":"2011","unstructured":"Chung SJ, Kwon YJ, Park MC, Park YB, Lee SK (2011) The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 52:113\u2013120","journal-title":"Yonsei Med J"},{"key":"2116_CR26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1471-4906(03)00079-6","volume":"24","author":"MG Netea","year":"2003","unstructured":"Netea MG, van der Meer JW, van Deuren M, Kullberg BJ (2003) Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 24:254\u2013258","journal-title":"Trends Immunol"},{"key":"2116_CR27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","volume":"94","author":"KK Machavaram","year":"2013","unstructured":"Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR (2013) A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther 94:260\u2013268","journal-title":"Clin Pharmacol Ther"},{"key":"2116_CR28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","volume":"87","author":"LP Rivory","year":"2002","unstructured":"Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87:277\u2013280","journal-title":"Br J Cancer"},{"key":"2116_CR29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","volume":"39","author":"LJ Dickmann","year":"2011","unstructured":"Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415\u20131422","journal-title":"Drug Metab Dispos"},{"key":"2116_CR30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0009-9236(97)90100-4","volume":"61","author":"M Tallgren","year":"1997","unstructured":"Tallgren M, Olkkola KT, Sepp\u00e4l\u00e4 T, H\u00f6ckerstedt K, Lindgren L (1997) Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 61:655\u2013661","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2116-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T20:01:34Z","timestamp":1568318494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2116-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2116"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2116-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]}}}